-
1 week ago | 
onclive.com | Ritu Salani |Kathleen Moore
Author(s):,Panelists discuss how evolving insights into HER2 expression—drawn from parallels with breast cancer—highlight the need for standardized HER2 testing in gynecologic oncology, as emerging data on HER2-low status and variability in current testing approaches underscore both the therapeutic potential of antibody-drug conjugates (ADCs) and the challenges of implementing precision medicine in this setting.
-
1 week ago | 
onclive.com | Ritu Salani |Kathleen Moore
Author(s):,Panelists discuss how antibody-drug conjugates (ADCs) and molecular testing are reshaping treatment strategies in ovarian and endometrial cancers by enabling more personalized, targeted care, while addressing practical challenges such as tissue limitations, tumor heterogeneity, and the evolving role of liquid biopsy in optimizing diagnostic accuracy.
-
Feb 1, 2025 | 
onclive.com | Kathleen Moore
CommentaryVideoFebruary 1, 2025Author(s):Kathleen N. Moore, MD, MS, discusses the relationship between biomarker expression and efficacy with antibody-drug conjugates in ovarian cancer. Kathleen N.
-
Nov 27, 2024 | 
onclive.com | Kathleen Moore
CommentaryVideoNovember 27, 2024Author(s):“We have had 2 important [developments] in the past…2 years. The first is mirvetuximab soravtansine, which is now fully FDA approved and is pending global approvals.”Kathleen N.
-
Nov 19, 2024 | 
onclive.com | Kathleen Moore
CommentaryVideoNovember 19, 2024Author(s):Kathleen N. Moore, MD, MS, discusses adverse effects associated with the use of antibody-drug conjugates for the treatment of gynecologic cancers. “We are still learning how to predict and mitigate [ADC-related toxicities] earlier so that we don’t have deaths. All of these drugs have unfortunately been compromised by deaths, mainly due to ILD, which is the toxicity that we worry most about with ADCs.”Kathleen N.
-
Nov 4, 2024 | 
onclive.com | Kathleen Moore
Kathleen N. Moore, MD, MS, professor, Section of Gynecologic Oncology, associate director, Clinical Research, Stephenson Cancer Center, director, Oklahoma TSET Phase I Program, University of Oklahoma College of Medicine, The University of Oklahoma Health Sciences, discusses the evolving treatment landscape for patients with platinum-resistant ovarian cancer, emphasizing the importance of redefining resistance parameters to guide treatment decisions more effectively.
-
Nov 20, 2023 | 
onclive.com | Kathleen Moore
Kathleen N. Moore, MD, MS, associate director, Clinical Research, the Stephenson Cancer Center, director, Oklahoma TSET Phase I Program, professor, Section of Gynecologic Oncology, The University of Oklahoma College of Medicine, discusses continued efforts to target the immune system in ovarian cancer through the use of immunotherapy, as well as alternative strategies being explored in this tumor type.
-
Sep 6, 2023 | 
onclive.com | Kathleen Moore
Kathleen N. Moore, MD, MS, associate director, Clinical Research, Stephenson Cancer Center, director, Oklahoma TSET Phase I Program, professor, Section of Gynecologic Oncology, The University of Oklahoma College of Medicine, discusses the design of the ongoing, first-in-human, phase 1/2 study (NCT03564340) of the MUC16- and CD3-targeted bispecific antibody ubamatamab (REGN4018) alone or in combination with cemiplimab-rwlc (Libtayo) in patients with recurrent ovarian cancer.
-
Aug 21, 2023 | 
onclive.com | Kathleen Moore
Kathleen N. Moore, MD, MS, associate director, Clinical Research, the Stephenson Cancer Center, director, Oklahoma TSET Phase I Program, professor, Section of Gynecologic Oncology, The University of Oklahoma College of Medicine, discusses the eligibility criteria for the ongoing, first-in-human, phase 1/2 study (NCT03564340) of ubamatamab (REGN4018), a MUC16- and CD3-targeted bispecific antibody, alone or in combination with cemiplimab-rwlc (Libtayo) in patients with recurrent ovarian cancer.
-
Jul 29, 2023 | 
onclive.com | Kathleen Moore
Kathleen N. Moore, MD, MS, associate director of Clinical Research, the Stephenson Cancer Center, director of the Oklahoma TSET Phase I Program, professor, the Section of Gynecologic Oncology, The University of Oklahoma College of Medicine, discusses the investigation of ubamatamab (REGN4018) alone or in combination with cemiplimab-rwlc (Libtayo) in patients with recurrent ovarian cancer.
